Webinar: Avoiding Common Pitfalls in Cell and Gene Therapy Trials
July 30, 2021 at 10:29 am EDT
Share
Cell and gene therapies hold tremendous potential to advance patient care but there are many challenges and complexities to consider for conducting clinical trials. As a leader in this area (we have managed or provided services for over 140 trials), key experts at Medpace participated in a recent webinar to share lessons-learned from being at the forefront of this exciting area of clinical development. Listen in as Medpace's Regulatory Submissions Manager, Jan Ohotski, and Clinical Trial Manager, Elizabeth Shepherd, discuss how to operationalize advance therapy clinical trials using hard-won lessons learned from Medpace's years of experience.
Our experts dive into:
Cell and gene therapy background
Regulatory and operational hurdles in developing advanced therapies
Strategies to accelerate development and reduce timeline delays associated with potential pitfalls
Real-world case studies and lessons learned while conducting cell and gene clinical trials
Watch the Webinar
We would welcome the opportunity to talk about your upcoming clinical development in gene and cell therapies. Learn more about our capabilities in advanced therapies and contact us to connect with our internal experts.
You may also be interested in this recent whitepaper: The Intersection of Rare Disease and Advanced Therapies.
Attachments
Original document
Permalink
Disclaimer
Medpace Holdings Inc. published this content on 30 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 July 2021 14:28:04 UTC.
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.